Ultrasound Guided Axillary Access vs Standard Fluoroscopic Technique for Cardiac Lead Implantation: ZEROFLUOROAXI TRIAL

Sponsor
University Hospital of Ferrara (Other)
Overall Status
Recruiting
CT.gov ID
NCT05101720
Collaborator
(none)
280
1
2
14
20.1

Study Details

Study Description

Brief Summary

Single center, randomized trial (1:1 fashion) to asses the safety and the feasibility of the ultrasound guided venous puncture vs standard fluoroscopic technique in patients undergoing pacemaker or implantable cardioverter-defibrillator implantations.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Ultrasound Guided Axillary Venous Access
  • Procedure: Fluoroscopy-Guided Axillary Venous Access
N/A

Detailed Description

Rationale: axillary, cephalic and subclavian venous accesses are commonly used in pacemaker and implantable cardioverter defibrillator implantations. Axillary puncture and cephalic vein surgical cutdown are both recommended in international guidelines due to low risk of pneumothorax and chronic lead complications. Sometimes cephalic vein is not available. Today axillary puncture is performed under fluoroscopic view and some complications still exist with this venous access as pneumothorax and arterial puncture. Axillary vein direct visualization can be obtained with standard venography or with ultrasound. With direct visualization and puncture of the axillary vein under ultrasound guidance venography with radiocontrast could be avoided. Less radiation exposure for patient and operator and direct visualization of the needle are possible with lower periprocedural complications using ultrasound. Despite the great interest for ultrasound guided axillary puncture up today we have few data on its feasibility. Our hypothesis is that ultrasound guided axillary access is more safe and more feasible than the standard fluoroscopic technique.

We decided to enroll all the patients undergoing standard transvenous pacemaker or cardioverter implantable defibrillator. We randomize the patients with 1:1 fashion to axillary venous access under fluoroscopic guidance or to ultrasound guided axillary venous access.

Obiectives: to asses safety, feasibility of the ultrasound guided venous puncture.

Main Endpoint: composite of pneumothorax, pocket hematoma, arterial puncture, pocket or device infection, hemothorax at 30 days.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
280 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Ultrasound Guided Axillary Access vs Standard Fluoroscopic Technique for Cardiac Lead Implantation
Actual Study Start Date :
Nov 1, 2021
Anticipated Primary Completion Date :
Nov 30, 2022
Anticipated Study Completion Date :
Dec 31, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Ultrasound Guided Axillary Access

Direct visualization of axillary vein with ultrasound will be obtained and used as a guidance for venous puncture.

Procedure: Ultrasound Guided Axillary Venous Access
Direct visualization of axillary vein will be obtained with ultrasound sterile linear probe.

Active Comparator: Fluoroscopic Guided Axillary Access

Standard technique: using the intersection of the lateral borders of the second and third rib as a radiological landmarks.

Procedure: Fluoroscopy-Guided Axillary Venous Access
Fluoroscopic landmarks will be used and axillary venous puncture will be performed without ultrasound

Outcome Measures

Primary Outcome Measures

  1. Composite of pneumothorax, pocket hematoma, arterial puncture, pocket or device infection, hemothorax at 30 days. [One month after index procedure]

    Composite of pneumothorax, pocket hematoma, arterial puncture, pocket or device infection, hemothorax at 30 days.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 120 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Need of a standard transvenous pacemaker or implantable cardioverter defibrillator implantations

  • Age > 18 years

Exclusion Criteria:
  • Leadless pacemaker or subcutaneous ICD

Contacts and Locations

Locations

Site City State Country Postal Code
1 Azienda Ospedaliero-Universitaria di Ferrara Ferrara Italy 44124

Sponsors and Collaborators

  • University Hospital of Ferrara

Investigators

  • Principal Investigator: Matteo Bertini, MD, PhD, Università degli Studi di Ferrara

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Matteo Bertini, MD, PhD, Professor, University Hospital of Ferrara
ClinicalTrials.gov Identifier:
NCT05101720
Other Study ID Numbers:
  • CE-AVEC 555/2021/Sper/AOUFe
First Posted:
Nov 1, 2021
Last Update Posted:
Nov 23, 2021
Last Verified:
Nov 1, 2021
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Matteo Bertini, MD, PhD, Professor, University Hospital of Ferrara
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 23, 2021